Home » Stocks » CDXC

ChromaDex Corporation (CDXC)

Stock Price: $13.93 USD -4.81 (-25.67%)
Updated Feb 26, 2021 4:00 PM EST - Market closed
After-hours: $14.15 +0.22 (1.58%) Feb 26, 7:58 PM
Market Cap 868.91M
Revenue (ttm) 56.90M
Net Income (ttm) -22.68M
Shares Out 61.70M
EPS (ttm) -0.38
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day February 26
Last Price $13.93
Previous Close $18.74
Change ($) -4.81
Change (%) -25.67%
Day's Open 20.24
Day's Range 13.76 - 20.54
Day's Volume 28,499,207
52-Week Range 2.50 - 23.66

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Business Wire - 3 days ago

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #COVID19research--ChromaDex Corp. (NASDAQ: CDXC) today announced results from the study “Combined Metabolic Activators Accelerates Recovery in Mild-to-Mo...

Benzinga - 5 days ago

ChromaDex Corp (NASDAQ: CDXC) enters into a securities purchase agreement to sell $25 million in common stock via a private placement led by a new international investor. The company will sell...

Business Wire - 5 days ago

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #CellularHealth--ChromaDex Corp. (NASDAQ: CDXC) announced today that it has entered into a securities purchase agreement for the sale of $25.0 million of...

Business Wire - 1 week ago

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #CellularHealth--ChromaDex Corp. (NASDAQ:CDXC) announced that it will hold a conference call on Wed., March 10, 2021 at 4:30 p.m. ET to discuss its finan...

Benzinga - 2 weeks ago

ChromaDex was one of the sponsors for the Benzinga Global Small Cap Conference that took place on December 8-9, 2020. The information contained in this article in no way represents investment ...

Business Wire - 3 weeks ago

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #CellularHealth--ChromaDex Corp. (NASDAQ: CDXC) today announced results from the study “Combined Metabolic Cofactor Supplementation Reduces Liver Fat in ...

Zacks Investment Research - 2 months ago

ChromaDex (CDXC) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

Business Wire - 3 months ago

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #CellularHealth--ChromaDex Corp. (NASDAQ:CDXC) announced today the initiation of a human clinical trial of Niagen® (nicotinamide riboside, or NR) investi...

Business Wire - 3 months ago

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #CellularHealth--ChromaDex Corp. (NASDAQ:CDXC) announced today the exclusive launch of its TRU NIAGEN® EX Stick Packs with Watsons Hong Kong, available o...

Seeking Alpha - 3 months ago

Tru Niagen, CDXC's patented product, shows strong promise in billion dollar markets. Market underestimates monopoly length by ~3x.

Seeking Alpha - 3 months ago

ChromaDex's (CDXC) CEO Rob Fried on Q3 2020 Results - Earnings Call Transcript

Zacks Investment Research - 3 months ago

ChromaDex (CDXC) delivered earnings and revenue surprises of 36.36% and -0.81%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Business Wire - 3 months ago

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #CellularHealth--ChromaDex Corp. (Nasdaq:CDXC) today reported third quarter financial results. 2020 Third Quarter and Recent Highlights Total net sales o...

Benzinga - 3 months ago

On Wednesday, November 04, ChromaDex (NASDAQ: CDXC) will release its latest earnings report. Check out Benzinga's preview to understand the implications.

Business Wire - 3 months ago

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #CellularHealth--ChromaDex Corp. (NASDAQ:CDXC) announced that it will hold a conference call on Wed., November 4, 2020 at 4:30 p.m. ET to discuss its fin...

Business Wire - 4 months ago

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #CellularHealth--ChromaDex Corp. (NASDAQ:CDXC) today highlighted a new study published in The European Molecular Biology Organization Journal looking at ...

Business Wire - 4 months ago

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #CellularHealth--ChromaDex Corp. (NASDAQ:CDXC) today announced its flagship ingredient, Tru Niagen®, is now available in Nestlé Health Science’s new Cell...

Seeking Alpha - 4 months ago

ChromaDex: Blazing Ahead Of Ponce De Leon

Business Wire - 4 months ago

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #CellularHealth--ChromaDex Corp. (NASDAQ:CDXC) today highlighted a new study from Nature Immunology that found nicotinamide riboside (NR) helped energize...

Business Wire - 4 months ago

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #CellularHealth--ChromaDex Corp. (NASDAQ:CDXC) today announced that results from the study “Combined metabolic cofactor supplementation accelerates recov...

Business Wire - 5 months ago

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #CellularHealth--ChromaDex Corp. (NASDAQ:CDXC) today announced new preclinical research published in Investigative Ophthalmology & Visual Science finding...

Business Wire - 6 months ago

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #CellularHealth--ChromaDex Corp. (NASDAQ:CDXC) today announced that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Kevin Farr, will...

Seeking Alpha - 6 months ago

Week 35 MDA Breakout Forecast: Short-Term Picks To Give You An Edge

Other stocks mentioned: AAPL, ALDX, CVX, HD, INTC, JNJ, MRK, NAD, VZ
Business Wire - 6 months ago

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #CellularHealth--ChromaDex Corp. (NASDAQ:CDXC) today announced the 11th published human trial on its patented NAD-boosting nutrient Niagen®, further high...

Seeking Alpha - 6 months ago

ChromaDex Corporation (CDXC) CEO Rob Fried on Q2 2020 Results - Earnings Call Transcript

Zacks Investment Research - 6 months ago

ChromaDex (CDXC) delivered earnings and revenue surprises of 45.45% and 12.71%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Business Wire - 6 months ago

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #CellularHealth--ChromaDex Corp. (NASDAQ:CDXC) today reported second quarter 2020 financial results.

Zacks Investment Research - 6 months ago

ChromaDex (CDXC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Business Wire - 6 months ago

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #CellularHealth--ChromaDex Corp. (NASDAQ:CDXC) announced that it will hold a conference call on Thurs.

Business Wire - 7 months ago

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #AutismResearch--ChromaDex Corp. (NASDAQ:CDXC) today announced the results of a new preclinical study published in Nature Scientific Reports investigatin...

Business Wire - 7 months ago

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #CellularHealth--ChromaDex Corp. (NASDAQ:CDXC) today announced the Company has signed its 200th material transfer agreement (MTA) through its global Chro...

Business Wire - 7 months ago

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #CellularHealth--ChromaDex Corp. (NASDAQ:CDXC) today announced the latest preclinical findings indicating Niagen® (patented nicotinamide riboside) inhibi...

Business Wire - 7 months ago

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #CellularHealth--ChromaDex Corp. (NASDAQ:CDXC) announced today the initiation of a preclinical study in collaboration with the National Institute of Alle...

Business Wire - 7 months ago

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #CellularHealth--ChromaDex Corp. (NASDAQ:CDXC) today announced the results of multiple new preclinical studies that illustrate the multifaceted potential...

Seeking Alpha - 9 months ago

ChromaDex Corporation's (CDXC) CEO Rob Fried on Q1 2020 Results - Earnings Call Transcript

Zacks Investment Research - 9 months ago

ChromaDex (CDXC) delivered earnings and revenue surprises of 18.18% and 4.25%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 10 months ago

ChromaDex (CDXC) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.

GlobeNewsWire - 11 months ago

ChromaDex Partners with Matakana Health Limited to Bring Tru Niagen to Australia

GlobeNewsWire - 11 months ago

LOS ANGELES, March 12, 2020 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC) seeks to correct statements made by an unaffiliated third-party, Merkel Media Group on behalf of its unnamed cli...

Seeking Alpha - 11 months ago

ChromaDex Corp. (CDXC) CEO Rob Fried on Q4 2019 Results - Earnings Call Transcript

Zacks Investment Research - 11 months ago

ChromaDex (CDXC) delivered earnings and revenue surprises of 8.33% and 2.23%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Benzinga - 11 months ago

ChromaDex (NASDAQ:CDXC) reported Q4 results. Quarterly Results • Earnings came in at a loss of $0.11 per share, in line with the estimate.

Zacks Investment Research - 11 months ago

ChromaDex (CDXC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 1 year ago

Preclinical study demonstrates the effects of short-term nicotinamide riboside (NR) supplementation in preventing hearing loss in animal models Preclinical study demonstrates the effects of sh...

GlobeNewsWire - 1 year ago

Tru Niagen® to launch in Persona’s customized vitamin and nutritional supplement delivery service Tru Niagen® to launch in Persona’s customized vitamin and nutritional supplement delivery service

GlobeNewsWire - 1 year ago

ChromaDex launches new research tools for the CBD industry with line of reference standards ChromaDex launches new research tools for the CBD industry with line of reference standards

GlobeNewsWire - 1 year ago

ChromaDex receives authorizations to sell its patented, NAD+ boosting nicotinamide riboside chloride in the European Union and in Australia with market exclusivity ChromaDex receives authoriza...

GlobeNewsWire - 1 year ago

Study expands on recently published preclinical data that showed improvements in aerobic performance following supplementation with ChromaDex’s novel form of vitamin B3 Study expands on recent...

GlobeNewsWire - 1 year ago

LOS ANGELES, Dec. 16, 2019 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC) announced today that Nutritional Outlook® , a leading publication for the nutraceuticals industry, recently awa...

GlobeNewsWire - 1 year ago

Tru Niagen® Pro 500 to be distributed exclusively through licensed healthcare practitioners Tru Niagen® Pro 500 to be distributed exclusively through licensed healthcare practitioners

About CDXC

ChromaDex Corporation operates as a nutraceutical company. The company offers Nicotinamide riboside (NIAGEN), a novel form of vitamin B3 for enhancing nicotinamide adenine dinucleotide (NAD) level used for healthy aging; and Immulina, a spirulina extract and compound, which is used for improving human immune function. It also provides reference standards and fine chemicals to conduct quality control of raw materials and consumer products in dietary supplements, cosmetics, food and beverages, and pharmaceutical industries. The company markets an... [Read more...]

Industry
Biotechnology
CEO
Robert Fried
Employees
110
Stock Exchange
NASDAQ
Ticker Symbol
CDXC
Full Company Profile

Financial Performance

In 2019, ChromaDex's revenue was $46.29 million, an increase of 46.69% compared to the previous year's $31.56 million. Losses were -$32.15 million, -3.51% less than in 2018.

Financial Statements

Analyst Forecasts

According to 6 analysts, the average rating for ChromaDex stock is "Strong Buy." The 12-month stock price forecast is 7.90, which is a decrease of -43.29% from the latest price.

Price Target
$7.90
(-43.29% downside)
Analyst Consensus: Strong Buy